---
title: "Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294964913.md"
description: "The enrollment for the KT-621 (STAT6) BROADEN2 Phase 2b AD trial has been finished nearly six months earlier than the expected timeline. Data from the trial is anticipated to be available by the end of 2026."
datetime: "2026-08-05T11:55:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294964913.md)
  - [en](https://longbridge.com/en/news/294964913.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294964913.md)
---

# Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

The enrollment for the KT-621 (STAT6) BROADEN2 Phase 2b AD trial has been finished nearly six months earlier than the expected timeline. Data from the trial is anticipated to be available by the end of 2026.

### Related Stocks

- [KYMR.US](https://longbridge.com/en/quote/KYMR.US.md)

## Related News & Research

- [KYMR: Q2 2026 revenue surged, net loss narrowed, and clinical pipeline advanced toward key milestones](https://longbridge.com/en/news/294977444.md)
- [Kymera Therapeutics (NASDAQ:KYMR) Releases Earnings Results, Beats Estimates By $0.09 EPS](https://longbridge.com/en/news/295001059.md)
- [KYMR: KT-621 and KT-579 advance rapidly, with $1.5B cash runway supporting late-stage pipeline](https://longbridge.com/en/news/294987182.md)
- [Kymera Therapeutics (KYMR) Could Be 23% Undervalued On Its New CMO Appointment](https://longbridge.com/en/news/294590421.md)
- [Kymera Therapeutics posts corporate deck outlining push to develop oral targeted protein degraders for immunology](https://longbridge.com/en/news/294964332.md)